Comparative bioequivalence of 1 mg and 4 mg tacrolimus extended-release tablets: randomized, open label, fully replicate, crossover trials in healthy adult subjects

Jay Kumar Sharma, Deepak Bunger, Hemant Zaveri, Alok Chaturvedi · 2026

Read Comparative bioequivalence of 1 mg and 4 mg tacrolimus extended-release tablets: randomized, open label, fully replicate, crossover trials in healthy adult subjects by Jay Kumar Sharma, Deepak Bunger, Hemant Zaveri, Alok Chaturvedi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13284695.txt.

Description

Jay Kumar Sharma and colleagues ran bioequivalence trials in 2026 for a generic long-acting form of tacrolimus, a drug that prevents organ rejection after transplant. The test tablets, made in India at one and four milligram strengths, were compared with the branded reference product. Healthy adults aged eighteen to forty-five took single doses in a randomised crossover design, each person cycling through test and reference products under both fasting and fed conditions.

Across the four study arms, about eighty-five subjects each, blood measures of drug exposure and peak levels matched the reference within the acceptance limits set by European regulators. Variability checks also passed. Side effects were monitored throughout, and the product was judged well tolerated. The authors call it an acceptable alternative, while noting transplant patients still need their own confirmatory studies.

Catalog record

CREATORJay Kumar Sharma, Deepak Bunger, Hemant Zaveri, Alok Chaturvedi
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13284695

Browse the full library · About the Tower of Babel